Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHBP | P24387 | 1/20 | 0.39 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.31 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3669666 | 0.87 | BACE1 (0.37) | CRHBPCRHR2 | |
| SCHEMBL22951353 | 0.80 | IDO1 (0.38) | KDM4ECYP3A4CYP2C19HIF1AIDO1 | |
| SCHEMBL3837662 | 0.75 | ACHE (0.40) | CRHBPCRHR2KDM4ECYP3A4CYP2C19 | |
| SCHEMBL3837501 | 0.75 | CRHBP (0.39) | CRHBPCRHR2KDM4ECYP3A4CYP2C19 | |
| SCHEMBL1294228 | 0.71 | TDP1 (0.45) | CRHBPCRHR2KDM4ECYP3A4CYP2C19 | |
| SCHEMBL1616369 | 0.71 | MAOA (0.40) | KDM4ECYP3A4CYP2C19HIF1ALMNA | |
| SCHEMBL17311004 | 0.71 | DPP4 (0.47) | CRHBPCRHR2KDM4ELMNA | |
| SCHEMBL492057 | 0.71 | DPP4 (0.47) | CRHBPCRHR2KDM4ELMNA | |
| SCHEMBL29746469 | 0.70 | CYP1A2 (0.46) | CRHBPCRHR2CYP3A4MAOAMAOB | |
| SCHEMBL239860 | 0.70 | CYP1A2 (0.46) | CRHBPCRHR2CYP3A4MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2139879-A1 | QUINOLINE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | AstraZeneca AB (SE) | 2010-01-06 | — | — | EP | claimed |
| US-20080234319-A1 | 6-chloro-N-{[(1S,3S)-1-hydroxy-3-methylcyclohexyl]methyl}-2-[(3S)-3-hydroxypyrrolidin-1-yl]quinoline-5-carboxamide; rheumatoid arthritis | ASTRAZENECA AB (SE) | 2008-09-25 | — | — | US | claimed |
| WO-2008114002-A1 | QUINOLINE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | ASTRAZENECA AB (SE) | 2008-09-25 | — | — | WO | claimed |
| EP-2139879-B1 | QUINOLINE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | ASTRAZENECA AB (SE) | 2012-07-11 | — | — | EP | disclosed |
| US-7964616-B2 | 6-chloro-N-{[(1S,3S)-1-hydroxy-3-methylcyclohexyl]methyl}-2-[(3S)-3-hydroxypyrrolidin-1-yl]quinoline-5-carboxamide; rheumatoid arthritis | ASTRAZENECA AB (SE) | 2011-06-21 | — | — | US | disclosed |
| EP-2139879-A1 | QUINOLINE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | AstraZeneca AB (SE) | 2010-01-06 | — | — | EP | disclosed |
| US-20080234319-A1 | 6-chloro-N-{[(1S,3S)-1-hydroxy-3-methylcyclohexyl]methyl}-2-[(3S)-3-hydroxypyrrolidin-1-yl]quinoline-5-carboxamide; rheumatoid arthritis | ASTRAZENECA AB (SE) | 2008-09-25 | — | — | US | disclosed |
| WO-2008114002-A1 | QUINOLINE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | ASTRAZENECA AB (SE) | 2008-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234319-A1 | 6-chloro-N-{[(1S,3S)-1-hydroxy-3-methylcyclohexyl]methyl}-2-[(3S)-3-hydroxypyrrolidin-1-yl]quinoline-5-carboxamide; rheumatoid arthritis | CNKSR1, HRH4, HRH1 | CRHBP 3258/4885CRHR2 1547/4885KDM4E 398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.